Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01467791

Acronym

RESAPH

Enrollment

300

Registered

2011-11-09

Start date

2011-11-30

Completion date

2018-01-31

Last updated

2015-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension, Sarcoidosis

Keywords

ambrisentan, Bosentan, Iloprost

Brief summary

Registry to follow patients with sarcoidosis associated pulmonary hypertension

Detailed description

This is a multi center registry of sarcoidosis associated pulmonary hypertension (SAPH). With this registry, the investigators will characterize the demographics, clinical course, hemodynamics, pulmonary physiology, and disease management of sarcoidosis associated pulmonary hypertension on the United States. The investigators will also compare these features to non-US sites.

Interventions

OTHERObservation

Observe patients

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Patients with sarcoidosis as defined by the ATS/WASOG statement * Patients with pulmonary hypertension as confirmed by right heart catheterization * Patients willing to provide written informed consent

Exclusion criteria

* Unwillingness to provide assurance that they will complete the follow up visits for the study

Design outcomes

Primary

Measure	Time frame	Description
Survival	4 years	Mortality during time of study

Secondary

Measure	Time frame	Description
Disease management	4 years	Examine initial and follow up management

Countries

United States

Contacts

Primary ContactRobert P Baughman, MD

bob.baughman@uc.edu513-584-5225

Backup ContactRebecca Ingledue

513-584-6252

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026